Lupin Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has launched Risperidone Long-Acting Injectable in the U.S. market with 180-day Competitive Generic Therapy (CGT) exclusivity from the FDA. This is the first product from Lupin's proprietary long-acting injectable platform called PrecisionSphere. The 180-day CGT exclusivity means Lupin will be the sole generic supplier of this product for six months, protecting it from competition. This marks an important milestone as Lupin enters the complex long-acting injectable space with its own in-house technology.
Positive for shareholders — the product launch opens a new revenue stream in the lucrative U.S. market, and the 180-day exclusivity provides a window of high-margin sales before generic competition begins. It also validates Lupin's PrecisionSphere platform, which could lead to more such launches in the future.